cisatracurium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
neuromuscular blocking agents with rigid structure 661 96946-42-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cisatracurium besylate
  • cisatracurium besilate
  • cisatracurium
  • Molecular weight: 929.16
  • Formula: C53H72N2O12
  • CLOGP: 3.30
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 0
  • TPSA: 126.44
  • ALOGS: -7.63
  • ROTB: 26
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.65 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.14 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.62 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 2 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.261 Moderate 0.70
caco2-efflux Caco-2 efflux ratio (BA/AB) 14.962 Moderate 0.70
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.033 10^-6 cm/s Moderate 0.70
dh-clint Dog hepatocyte intrinsic clearance 9.183 uL/min/10^6 cells Moderate 0.70
dppb Dog plasma protein binding (% unbound) 40.280 % Moderate 0.70
fcs-ppb Fetal calf serum protein binding (% unbound) 58.160 % Moderate 0.70
herg hERG pIC50 4.719 pIC50 Moderate 0.70
hh-clint Human hepatocyte intrinsic clearance 5.297 uL/min/10^6 cells Moderate 0.70
hlm-clint Human liver microsomal intrinsic clearance 115.345 uL/min/mg protein Moderate 0.70
hppb Human plasma protein binding (% unbound) 34.060 % Moderate 0.70
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.613 Moderate 0.70
mh-clint Mouse hepatocyte intrinsic clearance 61.235 Moderate 0.70
mppb Mouse plasma protein binding (% unbound) 38.030 Moderate 0.70
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 9.311 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 70.820 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 39.811 uL/min/10^6 cells Moderate 0.70
rh-fuinc Rat hepatocyte fraction unbound in incubation 78.330 % Moderate 0.70
rppb Rat plasma protein binding (% unbound) 46.670 % Moderate 0.70
solubility-dd Solubility at pH 7.4 in DMSO 872.971 uM Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 1995 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 389.03 45.84 107 2950 31510 90593880
Anaesthetic complication neurological 240.68 45.84 38 3019 703 90624687
Anaphylactic reaction 161.71 45.84 72 2985 87452 90537938
Hypotension 115.66 45.84 92 2965 325305 90300085
Mixed liver injury 103.71 45.84 28 3029 7595 90617795
Myoclonus 89.77 45.84 31 3026 19137 90606253
Cardiac arrest 83.64 45.84 49 3008 104886 90520504
Cardiogenic shock 82.38 45.84 31 3026 24437 90600953
Bronchospasm 72.49 45.84 27 3030 20682 90604708
Drug interaction 71.05 45.84 65 2992 276388 90349002
Propofol infusion syndrome 66.39 45.84 14 3043 1325 90624065
Skin test positive 65.83 45.84 13 3044 887 90624503
Multiple organ dysfunction syndrome 59.97 45.84 34 3023 68302 90557088
Acute generalised exanthematous pustulosis 59.67 45.84 21 3036 13682 90611708
Bradycardia 56.05 45.84 35 3022 83812 90541578
Respiratory failure 54.06 45.84 39 3018 118379 90507011
Bronchopulmonary dysplasia 51.67 45.84 10 3047 614 90624776
Circulatory collapse 50.75 45.84 22 3035 24882 90600508
Hyperthermia malignant 49.85 45.84 11 3046 1287 90624103
Apnoea 47.07 45.84 16 3041 9398 90615992
Neurodevelopmental disorder 46.76 45.84 8 3049 245 90625145
Cardio-respiratory arrest 46.37 45.84 28 3029 63112 90562278

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 379.75 35.60 119 3253 23398 42594565
Anaesthetic complication neurological 267.98 35.60 47 3325 689 42617274
Hyperthermia malignant 246.25 35.60 54 3318 2604 42615359
Drug reaction with eosinophilia and systemic symptoms 150.28 35.60 71 3301 42004 42575959
Anaphylactic reaction 143.11 35.60 69 3303 42674 42575289
Rhabdomyolysis 126.80 35.60 78 3294 77941 42540022
Hypertransaminasaemia 101.36 35.60 35 3337 9192 42608771
Toxic epidermal necrolysis 98.04 35.60 46 3326 26704 42591259
Klebsiella infection 83.44 35.60 32 3340 11300 42606663
Hypoxia 75.01 35.60 54 3318 69732 42548231
Hypotension 66.28 35.60 91 3281 257540 42360423
Confusion postoperative 56.50 35.60 10 3362 154 42617809
Acute respiratory distress syndrome 56.26 35.60 33 3339 30075 42587888
Bronchospasm 56.10 35.60 25 3347 12860 42605103
Postoperative delirium 54.46 35.60 12 3360 588 42617375
Cyanosis 46.39 35.60 23 3349 15008 42602955
Cardiac arrest 44.88 35.60 49 3323 109271 42508692
Serotonin syndrome 44.81 35.60 27 3345 25818 42592145
Shock 41.85 35.60 27 3345 29094 42588869
Hyperthermia 41.07 35.60 20 3352 12554 42605409
Septic shock 40.98 35.60 43 3329 91629 42526334
Tachycardia 40.94 35.60 45 3327 101042 42516921
Vasoplegia syndrome 40.86 35.60 13 3359 2642 42615321
Pseudomonal sepsis 38.57 35.60 14 3358 4235 42613728
Nervous system disorder 37.89 35.60 21 3351 17174 42600789

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 753.36 37.35 223 5967 51323 110531786
Hyperthermia malignant 300.12 37.35 64 6126 3836 110579273
Anaphylactic reaction 287.48 37.35 136 6054 114164 110468945
Hypotension 177.82 37.35 180 6010 523669 110059440
Rhabdomyolysis 145.38 37.35 88 6102 120313 110462796
Drug reaction with eosinophilia and systemic symptoms 136.64 37.35 74 6116 82021 110501088
Bronchospasm 128.00 37.35 52 6138 30187 110552922
Cardiac arrest 121.29 37.35 95 6095 196658 110386451
Mixed liver injury 119.94 37.35 39 6151 12040 110571069
Hypoxia 105.53 37.35 74 6116 129441 110453668
Toxic epidermal necrolysis 105.25 37.35 55 6135 56672 110526437
Hypertransaminasaemia 90.08 37.35 38 6152 24217 110558892
Shock 80.01 37.35 45 6145 53543 110529566
Klebsiella infection 79.85 37.35 33 6157 19976 110563133
Cyanosis 76.42 37.35 36 6154 29705 110553404
Acute respiratory distress syndrome 74.92 37.35 43 6147 53155 110529954
Propofol infusion syndrome 73.82 37.35 19 6171 2570 110580539
Multiple organ dysfunction syndrome 71.99 37.35 63 6127 151647 110431462
Tachycardia 65.98 37.35 72 6118 226573 110356536
Myoclonus 61.19 37.35 32 6158 32966 110550143
Drug interaction 60.95 37.35 104 6086 500079 110083030
Cardiogenic shock 59.23 37.35 38 6152 57300 110525809
Skin test positive 58.21 37.35 14 6176 1435 110581674
Airway peak pressure increased 57.72 37.35 12 6178 633 110582476
Circulatory collapse 55.89 37.35 33 6157 42960 110540149
Serotonin syndrome 55.71 37.35 37 6153 59116 110523993
Bradycardia 55.27 37.35 55 6135 155462 110427647
Acute generalised exanthematous pustulosis 54.96 37.35 26 6164 21638 110561471
Ventricular fibrillation 54.46 37.35 32 6158 41281 110541828
Postoperative delirium 53.54 37.35 12 6178 903 110582206
Confusion postoperative 51.88 37.35 10 6180 358 110582751
Septic shock 51.04 37.35 53 6137 157475 110425634
Metabolic acidosis 50.48 37.35 43 6147 99701 110483408
Fatigue 50.33 37.35 5 6185 1215953 109367156
Hepatocellular injury 46.05 37.35 31 6159 50611 110532498
Apallic syndrome 46.05 37.35 11 6179 1095 110582014
Cardio-respiratory arrest 44.94 37.35 43 6147 115793 110467316
Hyperthermia 43.39 37.35 22 6168 21250 110561859
Pulseless electrical activity 42.16 37.35 20 6170 16737 110566372
Coma 40.60 37.35 41 6149 117828 110465281
Vasoplegia syndrome 39.92 37.35 14 6176 5425 110577684

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03AC11 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Other quaternary ammonium compounds
CHEBI has role CHEBI:48878 nicotinic antagonist
CHEBI has role CHEBI:51371 muscle relaxant
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175720 Nondepolarizing Neuromuscular Blocker
FDA PE N0000175732 Neuromuscular Nondepolarizing Blockade

Related Drugs by ATC class:

M03AC Other quaternary ammonium compounds 10 drugs
atracuriumdoxacuriumfazadiniumgallaminehexafluroniummivacuriumpancuroniumpipecuroniumrocuroniumvecuronium

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Disorder of lung contraindication 19829001 DOID:850
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of electrolytes contraindication 237840007
Malignant hyperthermia contraindication 405501007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholine receptor Ion channel ANTAGONIST IC50 8 WOMBAT-PK CHEMBL

External reference:

IDSource
4020957 VUID
N0000148433 NUI
D00759 KEGG_DRUG
96946-41-7 SECONDARY_CAS_RN
136561 RXNORM
C1096766 UMLSCUI
CHEMBL1201248 ChEMBL_ID
CHEMBL1200641 ChEMBL_ID
DB00565 DRUGBANK_ID
C101584 MESH_SUPPLEMENTAL_RECORD_UI
QX62KLI41N UNII
62887 PUBCHEM_CID
192613 MMSL
36562 MMSL
4455 MMSL
d03875 MMSL
005186 NDDF
005213 NDDF
108452005 SNOMEDCT_US
108453000 SNOMEDCT_US
372495006 SNOMEDCT_US
CHEBI:3721 CHEBI
7389 INN_ID
4020957 VANDF
4024019 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9160 INJECTION 10 mg INTRAVENOUS ANDA 29 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9396 INJECTION 2 mg INTRAVENOUS ANDA 29 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9397 INJECTION 2 mg INTRAVENOUS ANDA 29 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1098 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 28 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1103 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 28 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1208 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 28 sections
cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3150 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3152 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 0781-3153 INJECTION 10 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate Human Prescription Drug Label 1 31722-312 INJECTION 10 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate Human Prescription Drug Label 1 31722-313 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate Human Prescription Drug Label 1 31722-314 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate Human Prescription Drug Label 1 55150-284 INJECTION 10 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate Human Prescription Drug Label 1 55150-286 INJECTION 20 mg INTRAVENOUS ANDA 25 sections
Cisatracurium HUMAN PRESCRIPTION DRUG LABEL 1 63323-416 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 28 sections
Cisatracurium HUMAN PRESCRIPTION DRUG LABEL 1 63323-417 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 28 sections
Cisatracurium HUMAN PRESCRIPTION DRUG LABEL 1 63323-418 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 28 sections
Cisatracurium besylate Human Prescription Drug Label 1 65145-135 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate Human Prescription Drug Label 1 65145-136 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate Human Prescription Drug Label 1 65145-137 INJECTION 10 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate Human Prescription Drug Label 1 68083-486 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate Human Prescription Drug Label 1 68083-487 INJECTION 10 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate Human Prescription Drug Label 1 68083-488 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 70069-141 INJECTION 2 mg INTRAVENOUS ANDA 23 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 70069-151 INJECTION 10 mg INTRAVENOUS ANDA 23 sections
Cisatracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 70069-161 INJECTION 2 mg INTRAVENOUS ANDA 23 sections
Cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 70436-112 INJECTION 2 mg INTRAVENOUS ANDA 24 sections
Cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 70436-113 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 70436-114 INJECTION 10 mg INTRAVENOUS ANDA 24 sections
cisatracurium besylate HUMAN PRESCRIPTION DRUG LABEL 1 70710-1532 INJECTION 2 mg INTRAVENOUS ANDA 23 sections